{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:39:25Z","timestamp":1792618765269,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021316","name":"AstraZeneca Pharmaceuticals LP","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.anai.2026.09.737","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:45:13Z","timestamp":1789688713000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness of tezepelumab for patients with severe asthma in the United States: CROSSROADS-3"],"prefix":"10.1016","author":[{"given":"Jessica K.","family":"DeMartino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago Zuluaga","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Emmanuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee L.","family":"Gennarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temitope","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lindsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Llanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laren","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weily","family":"Soong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2026.09.737_bib0001","series-title":"Data, Statistics, and Surveillance: Asthma Surveillance Data","year":"2020"},{"issue":"5","key":"10.1016\/j.anai.2026.09.737_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss7005a1","article-title":"Asthma surveillance - United States, 2006-2018","volume":"70","author":"Pate","year":"2021","journal-title":"MMWR Surveill Summ."},{"key":"10.1016\/j.anai.2026.09.737_bib0003","series-title":"Presented at: 2022 AMCP Meeting","article-title":"Real-world asthma-related health care resource utilization and costs among patients with severe uncontrolled asthma","author":"Burnette","year":"2022"},{"issue":"7","key":"10.1016\/j.anai.2026.09.737_bib0004","first-page":"825","article-title":"Incremental cost burden among patients with severe uncontrolled asthma in the United States","volume":"29","author":"Burnette","year":"2023","journal-title":"J Manag Care Spec Pharm."},{"key":"10.1016\/j.anai.2026.09.737_bib0005","unstructured":"TEZSPIRE\u00ae pi. Prescribing information: TEZSPIRE (tezepelumab-ekko) injection, for subcutaneous use. Amgen Inc and AstraZeneca AB. Accessed June 30, 2023. Available at: https:\/\/den8dhaj6zs0e.cloudfront.net\/50fd68b9-106b-4550-b5d0-12b045f8b184\/e306dc06-d580-4457-b15f-9f28545ad63a\/e306dc06-d580-4457-b15f-9f28545ad63a_viewable_rendition__v.pdf"},{"issue":"7","key":"10.1016\/j.anai.2026.09.737_bib0006","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1007\/s12325-023-02514-0","article-title":"Efficacy of biologics in severe, uncontrolled asthma stratified by blood eosinophil count: a systematic review","volume":"40","author":"Korn","year":"2023","journal-title":"Adv Ther."},{"issue":"1","key":"10.1016\/j.anai.2026.09.737_bib0007","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.alit.2022.11.006","article-title":"Current summary of clinical studies on anti-TSLP antibody, tezepelumab, in asthma","volume":"72","author":"Kurihara","year":"2023","journal-title":"Allergol Int."},{"issue":"suppl 5","key":"10.1016\/j.anai.2026.09.737_bib0008","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.anai.2022.08.520","article-title":"Asthma exacerbations before and after tezepelumab treatment: a pooled analysis of PATHWAY and NAVIGATOR studies","volume":"129","author":"Mathur","year":"2022","journal-title":"Ann Allergy Asthma Immunol."},{"issue":"10","key":"10.1016\/j.anai.2026.09.737_bib0009","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.anai.2026.09.737_bib0010","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.anai.2026.09.737_bib0011","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir Med."},{"issue":"7","key":"10.1016\/j.anai.2026.09.737_bib0012","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1007\/s12325-025-03231-6","article-title":"Effectiveness and safety of tezepelumab in a diverse population of US patients with severe asthma: initial results of the PASSAGE study","volume":"42","author":"Lugogo","year":"2025","journal-title":"Adv Ther."},{"key":"10.1016\/j.anai.2026.09.737_bib0013","series-title":"Presented at: 2025 AAAAI\/WAO Joint Congress","article-title":"Substantial reduction in asthma exacerbations in patients with severe asthma with or without clinically relevant perennial allergy after 6 months of tezepelumab use: interim results from the Phase 4 PASSAGE study","author":"Akuthota","year":"2025"},{"issue":"1","key":"10.1016\/j.anai.2026.09.737_bib0014","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","article-title":"Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials","volume":"208","author":"Corren","year":"2023","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.anai.2026.09.737_bib0015","series-title":"Presented at: American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting","article-title":"Efficacy of tezepelumab in patients with severe, uncontrolled asthma and high baseline blood eosinophil counts","author":"Jain","year":"2022"},{"key":"10.1016\/j.anai.2026.09.737_bib0016","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2147\/JAA.S342391","article-title":"Tezepelumab for severe asthma: 1 drug targeting multiple disease pathways and patient types","volume":"17","author":"Panettieri","year":"2024","journal-title":"J Asthma Allergy."},{"issue":"6","key":"10.1016\/j.anai.2026.09.737_bib0017","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00316-2024","article-title":"Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies","volume":"64","author":"Wechsler","year":"2024","journal-title":"Eur Respir J."},{"issue":"6","key":"10.1016\/j.anai.2026.09.737_bib0018","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2500\/aap.2023.44.230061","article-title":"Impact of COVID-19 measures on exacerbation rates and healthcare visits in US asthma patients","volume":"44","author":"Karcher","year":"2023","journal-title":"Allergy Asthma Proc."},{"key":"10.1016\/j.anai.2026.09.737_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107802","article-title":"Temporal variation in the effectiveness of biologics in asthma: effect modification by changing patient characteristics","volume":"234","author":"Nopsopon","year":"2024","journal-title":"Respir Med."},{"key":"10.1016\/j.anai.2026.09.737_bib0020","article-title":"Impact of COVID-19 pandemic on asthma exacerbations: retrospective cohort study of over 500,000 patients in a national English primary care database","volume":"19","author":"Shah","year":"2022","journal-title":"Lancet Reg Health Eur."},{"issue":"2","key":"10.1016\/j.anai.2026.09.737_bib0021","doi-asserted-by":"crossref","first-page":"AB96","DOI":"10.1016\/j.jaci.2023.11.318","article-title":"The real-world effectiveness of tezepelumab in a cohort of patients with severe asthma","volume":"153","author":"Nopsopon","year":"2024","journal-title":"J Allergy Clin Immunol."},{"issue":"7","key":"10.1016\/j.anai.2026.09.737_bib0022","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s12325-024-02889-8","article-title":"Efficacy of tezepelumab in patients with severe, uncontrolled asthma across multiple clinically relevant subgroups in the NAVIGATOR study","volume":"41","author":"Carr","year":"2024","journal-title":"Adv Ther."},{"issue":"6","key":"10.1016\/j.anai.2026.09.737_bib0023","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.1016\/j.jval.2023.03.1368","article-title":"Patient characteristics, treatment patterns, and outcomes among early tezepelumab users: an early view claims data study","volume":"26","author":"Rane","year":"2023","journal-title":"Value Health."},{"issue":"1","key":"10.1016\/j.anai.2026.09.737_bib0024","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00408-026-00903-0","article-title":"The clinical and economic impact of biologic agents in asthma management: a systematic review","volume":"204","author":"Procacci","year":"2026","journal-title":"Lung."},{"issue":"9","key":"10.1016\/j.anai.2026.09.737_bib0025","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3349\/ymj.2024.0320","article-title":"Real-world effectiveness of omalizumab treatment in adult asthma patients","volume":"66","author":"Jang","year":"2025","journal-title":"Yonsei Med J."},{"issue":"6","key":"10.1016\/j.anai.2026.09.737_bib0026","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.anai.2022.02.017","article-title":"Real-world effectiveness of Benralizumab: results from the ZEPHYR 1 Study","volume":"128","author":"Chung","year":"2022","journal-title":"Ann Allergy Asthma Immunol."},{"key":"10.1016\/j.anai.2026.09.737_bib0027","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/JAA.S236609","article-title":"Real-world effectiveness of mepolizumab in patients with severe asthma: an examination of exacerbations and costs","volume":"13","author":"Llanos","year":"2020","journal-title":"J Asthma Allergy."},{"issue":"4","key":"10.1016\/j.anai.2026.09.737_bib0028","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.anai.2023.11.006","article-title":"Real-world effectiveness of dupilumab in patients with asthma: findings from the US ADVANTAGE study","volume":"132","author":"Blaiss","year":"2024","journal-title":"Ann Allergy Asthma Immunol."}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626011993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626011993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:00:16Z","timestamp":1792616416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626011993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"alternative-id":["S1081120626011993"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.09.737","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of tezepelumab for patients with severe asthma in the United States: CROSSROADS-3","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.09.737","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}